Genome-wide identification of structural variants in genes encoding drug targets: Possible implications for individualized drug therapy

Pharmacogenetics and Genomics

Volumn 22, Issue 7, 2012, Pages 471-483

  Rasmussen, Henrik Berg ^a   Dahmcke, Christina MacKeprang ^a  

^a Mental Health Centre St Hans   (Denmark)

Author keywords

Anatomical Therapeutic Chemical codes; copy number variation; drug targets; nutraceuticals; structural genomic variation

Indexed keywords

AMBENONIUM; ANILERIDINE; ATOMOXETINE; BETHANECHOL; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOBAZAM; ENTACAPONE; ETHOSUXIMIDE; ETHOTOIN; FOSPHENYTOIN SODIUM; GALANTAMINE; METHARBITAL; METHOHEXITAL; METHYLPHENOBARBITAL; METHYPRYLON; MOCLOBEMIDE; NEOSTIGMINE; NITRAZEPAM; NUTRACEUTICAL; OXCARBAZEPINE; PARAMETHADIONE; PENTOBARBITAL; PHENACEMIDE; PHENOBARBITAL; PRAZEPAM; PREGABALIN; PRILOCAINE; PRIMIDONE; UNINDEXED DRUG;

ARTICLE; COPY NUMBER VARIATION; DRUG STRUCTURE; DRUG TARGETING; GENE STRUCTURE; GENE TARGETING; GENETIC VARIABILITY; GENOME ANALYSIS; INDIVIDUALIZATION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 84862756979     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328352c770     Document Type: Article

References (56)

1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7:201-204. (Pubitemid 32822891)
2. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913. (Pubitemid 36736631)
3. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57:119-137. (Pubitemid 43261982)
4. Nies AS. Principles of therapeutics. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001. pp. 45-66.
5. Levy G. Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin Pharmacokinet 1998; 34:323-333. (Pubitemid 28162187)
6. Ueno K, Sato H. Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs. Hypertens Res 2011 [Epub ahead of print].
7. Johnson JA, Lima JJ. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 2003; 13:525-534. (Pubitemid 37159631)
8. Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 2006; 44:107-118. (Pubitemid 43082210)
9. Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM, Akkerhuis KM, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens 2011; 29:509-519.
10. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7:9-37.
11. Korbel JO, Kim PM, Chen X, Urban AE, Weissman S, Snyder M, et al. The current excitement about copy-number variation: how it relates to gene duplications and protein families. Curr Opin Struct Biol 2008; 18:366-374.
12. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526. (Pubitemid 350116943)
13. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997; 94:1544-1549. (Pubitemid 27087888)
14. Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol 2002; 13:1882-1892. (Pubitemid 36040777)
15. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34:D668-D672.
16. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36:D901-D906. (Pubitemid 351149842)
17. Chen X, Ji ZL, Chen YZ. TTD: Therapeutic Target Database. Nucleic Acids Res. 2002; 30:412-415. (Pubitemid 34679600)
18. Zhu F, Han B, Kumar P, Liu X, Ma X,Wei X, et al. Update of TTD: Therapeutic Target Database. Nucleic Acids Res 2010; 38:D787-D791.
19. Levy G. What are narrow therapeutic index drugs? Clin Pharmacol Ther 1998; 63:501-505. (Pubitemid 28277270)
20. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. Nat Genet 2004; 36:949-951. (Pubitemid 39167488)
21. Hek K, Tiemeier H, Newson RS, Luijendijk HJ, Hofman A, Mulder CL. Anxiety disorders and comorbid depression in community dwelling older adults. Int J Methods Psychiatr Res 2011; 20:157-168.
22. Beissbarth T, Speed TP. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004; 20:1464-1465. (Pubitemid 38931420)
23. Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. A highresolution survey of deletion polymorphism in the human genome. Nat Genet 2006; 38:75-81. (Pubitemid 43011885)
24. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, et al. Origins and functional impact of copy number variation in the human genome. Nature 2010; 464:704-712.
25. Cooper GM, Zerr T, Kidd JM, Eichler EE, Nickerson DA. Systematic assessment of copy number variant detection via genome-wide SNP genotyping. Nat Genet 2008; 40:1199-1203.
26. De Smith AJ, Tsalenko A, Sampas N, Scheffer A, Yamada NA, Tsang P, et al. Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy white males: implications for association studies of complex diseases. Hum Mol Genet 2007; 16:2783-2794. (Pubitemid 350048378)
27. Hinds DA, Kloek AP, Jen M, Chen X, Frazer KA. Common deletions and SNPs are in linkage disequilibrium in the human genome. Nat Genet 2006; 38:82-85. (Pubitemid 43011886)
28. Itsara A, Cooper GM, Baker C, Girirajan S, Li J, Absher D, et al. Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet 2009; 84:148-161.
29. Jakobsson M, Scholz SW, Scheet P, Gibbs JR, VanLiere JM, Fung HC, et al. Genotype, haplotype and copy-number variation in worldwide human populations. Nature 2008; 451:998-1003. (Pubitemid 351301742)
30. Locke DP, Sharp AJ, McCarroll SA, McGrath SD, Newman TL, Cheng Z, et al. Linkage disequilibrium and heritability of copy-number polymorphisms within duplicated regions of the human genome. Am J Hum Genet 2006; 79:275-290. (Pubitemid 44141826)
31. Matsuzaki H,Wang PH, Hu J, Rava R, Fu GK. High resolution discovery and confirmation of copy number variants in 90 Yoruba Nigerians. Genome Biol 2009; 10:R125.
32. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J,Wysoker A, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 2008; 40:1166-1174.
33. Perry GH, Ben-Dor A, Tsalenko A, Sampas N, Rodriguez-Revenga L, Tran CW, et al. The fine-scale and complex architecture of human copy-number variation. Am J Hum Genet 2008; 82:685-695.
34. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature 2006; 444:444-454. (Pubitemid 44809057)
35. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al. Large-scale copy number polymorphism in the human genome. Science 2004; 305:525-528. (Pubitemid 38971344)
36. Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, et al. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 2005; 77:78-88. (Pubitemid 40848038)
37. Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SF, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007; 17:1665-1674. (Pubitemid 350074862)
38. Wong KK, de Leeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet 2007; 80:91-104. (Pubitemid 46047653)
39. Kim JI, Ju YS, Park H, Kim S, Lee S, Yi JH, et al. A highly annotated wholegenome sequence of a Korean individual. Nature 2009; 460:1011-1015.
40. Kidd JM, Cooper GM, DonahueWF, Hayden HS, Sampas N, Graves T, et al. Mapping and sequencing of structural variation from eight human genomes. Nature 2008; 453:56-64. (Pubitemid 351630326)
41. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 2008; 452:872-876. (Pubitemid 351550870)
42. McKernan KJ, Peckham HE, Costa GL, McLaughlin SF, Fu Y, Tsung EF, et al. Sequence and structural variation in a human genome uncovered by shortread, massively parallel ligation sequencing using two-base encoding. Genome Res 2009; 19:1527-1541.
43. Gusev A, Lowe JK, Stoffel M, Daly MJ, Altshuler D, Breslow JL, et al. Whole population, genome-wide mapping of hidden relatedness. Genome Res 2009; 19:318-326.
44. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365:919-926.
45. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011; 10:446-456.
46. Mefford HC, Mulley JC. Genetically complex epilepsies, copy number variants and syndrome constellations. Genome Med 2010; 2:71.
47. Galan JJ, Buch B, Pedrinaci S, Jimenez-Gamiz P, Gonzalez A, Serrano-Rios M, et al. Identification of a 2244 base pair interstitial deletion within the human ESR1 gene in the Spanish population. J Med Genet 2008; 45:420-424. (Pubitemid 351977131)
48. Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V, et al. Consortium on Breast Cancer Pharmacogenomics (COBRA). Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther 2010; 88: 626-629.
49. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000; 25:197-220.
50. Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. HER-2 as a target for breast cancer therapy. Clin Cancer Res 2009; 15:1848-1852.
51. Lordick F. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 2011; 7:187-199.
52. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK. Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 1999; 274:16694-16700.
53. Petrelli A, Giordano S. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008; 15: 422-432. (Pubitemid 351472408)
54. Lauss M, Kriegner A, Vierlinger K, Noehammer C. Characterization of the drugged human genome. Pharmacogenomics 2007; 8:1063-1073. (Pubitemid 47423693)
55. Zhu M, Gao L, Li X, Liu Z, Xu C, Yan Y, et al. The analysis of the drug-targets based on the topological properties in the human protein-protein interaction network. J Drug Target 2009; 17:524-532.
56. Feuk L. Inversion variants in the human genome: role in disease and genome architecture. Genome Med 2010; 2:11.